Skip to main navigation Skip to search Skip to main content

A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The DAL-302 (dal-GenE-2) tria

Project: Research

Project Details

StatusActive
Effective start/end date08/8/25 → 08/30/27

Funding

  • DalCor Pharmaceuticals Canada Incorporated: $21,320.00